Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
The keenly awaited study of Lynparza in pancreatic cancer maintenance fails to show much beyond its headline primary endpoint of progression-free survival.
A first-line Keytruda study is nominally positive, but numerous questions remain before approval can be assured.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
The group’s Braftovi/Mektovi combo shows the potential of a targeted approach in colorectal cancer, so where is the competition?
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.